Lee Pharmaceuticals (LPHM) 0.0046 $LPHM 2015

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Lee Pharmaceuticals (LPHM) 0.0046 $LPHM

2015 Investigation Report on China's Insulin Lispro Market 2010-2019 Featuring Eli Lilly and Company & Gan & Lee Pharmaceuticals
PR Newswire Europe - Thu Aug 06, 9:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/963t94/investigation [http://www.researchandmarkets.com/research/963t94/investigation]) has announced the addition of the "Investigation Report on China's Insulin Lispro Market, 2010-2019" [http://www.researchandmarkets.com/research/963t94/investigation] report to their offering.
LLY: 86.14 (+2.37)

Research and Markets: Investigation Report on China's Insulin Lispro Market, 2010-2019 Featuring Eli Lilly and Company & Gan & Lee Pharmaceuticals
Business Wire - Thu Aug 06, 5:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l8n6ks/investigation) has announced the addition of the "Investigation Report on China's Insulin Lispro Market, 2010-2019" report to their offering.
LLY: 86.14 (+2.37)

Investigation Report on China's Insulin Lispro Market, 2010-2019 Featuring Eli Lilly and Company & Gan & Lee Pharmaceuticals
M2 - Thu Aug 06, 4:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8pbxrk/investigation) has announced the addition of the "Investigation Report on China's Insulin Lispro Market, 2010-2019" report to their offering. According to the statistics of International Diabetes Federation (IDF), in 2013, the prevalence of diabetes among adults aged from 20 to 79 was 8.3% and the number of diabetes patients has reached 382 million in the world, 80% of which come from middle income and low income countries and the figure demonstrates a fast rising trend. It is estimated that by 2035, there will be nearly 592 million people suffering from diabetes in the whole world. The number of diabetes patients in China was estimated to be 98.4 million in 2013, ranking first in the world, followed by India (65.1 million), USA (24.4 million), Brazil (11.9 million) and Russia (10.9 million). IDF estimates that by 2035, the number of diabetes patients in China will reach 143 million, still ranking first in the world while that in America will reach 29.7 million. The fast growth of diabetes in China and other developing countries has put a heavy burden on their social and economic development. There are about 90 million diabetes patients in today's China and 95% of them suffer from type 2 diabetes mellitus. And the number of potential patients might reach up to 200 million. For patients with type 1 diabetes mellitus, insulin is the only drug available. Besides, 30%-40% of type 2 diabetes will finally become insulin-dependent. Currently, the diabetic drug market at home and abroad both show rapid growth. Although international giants take up a large share, domestic enterprises are expected to break through in certain fields. The vast number of patients and demand for treatment will drive the diabetic drug market to expand. In recent years, insulin's share in the diabetic drug market has increasingly risen, 42% in the global market while nearly 40% in China. Insulin lispro is a fast-acting insulin analogue. Insulin lispro has one primary advantage over regular insulin for postprandial glucose control. It has a shortened delay of onset, avoiding episodes of hypoglycemia. In the late 1990s, insulin lispro made by Eli Lilly and Company entered China. Later insulin lispro made by Gan & Lee Pharmaceuticals also came into the market. After entering China, insulin lispro develops fast with annual sales rising from less than CNY 7 million in 2005 to CNY 142 million in 2014 and CAGR during 2005-2014 reaching up to 40.1%. Currently, insulin lispro in the Chinese market mainly come from Eli Lilly and Company and Gan & Lee Pharmaceuticals. According to this market survey, Eli Lilly and Company has a larger market share of over 99% in 2014 by sales value. Key Topics Covered: 1Related Concepts of Insulin Lispro 2 Market Profile of Insulin Lispro in China 3 Survey on Sales Value of Insulin Lispro in China, 2010-2014 4 Survey on Sales Volume of Insulin Lispro in China, 2010-2014 5 Survey on Market Share of Major Manufacturers of Insulin Lispro in China, 2010-2014 6 Survey on Market Share of Dosage Forms of Insulin Lispro in China, 2010-2014 7 Reference Price of Insulin Lispro in Chinese Hospitals in 2014 8 Major Manufacturers of Insulin Lispro in Chinese Market, 2010-2014 9 Market Outlook of Insulin Lispro in China, 2014-2018 Companies Mentioned - Eli Lilly and Company - Gan & Lee Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/8p...estigation
LLY: 86.14 (+2.37)

The Incidence of Diabetes inside China keeps Growing and the Market Size of Diabetes Drugs Has Expanded Each Year, Exceeding CNY 20 Billion in 2014
M2 - Thu Jun 11, 4:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/62kjcv/investigation) has announced the addition of the "Investigation Report on China's Insulin Glargine Market, 2010-2019" report to their offering. According to the statistics of International Diabetes Federation (IDF), in 2013, the prevalence of diabetes among adults aged from 20 to 79 was 8.3% and the number of diabetes patients reached 382 million in the world, 80% of which come from middle income and low income countries and the figure demonstrates a fast rising trend. It is estimated that by 2035, there will be nearly 592 million people suffering from diabetes in the whole world. The number of diabetes patients in China was estimated to be 98.4 million in 2013, ranking first in the world, followed by India (65.1 million), USA (24.4 million), Brazil (11.9 million) and Russia (10.9 million). IDF estimates that by 2035, the number of diabetes patients in China will reach 143 million, still ranking first in the world while in America it will reach 29.7 million. The fast growth rate of diabetes in China and other developing countries has put a heavy burden on their social and economic development. In China, the third generation of insulin is still in promotion period. Since its price is relatively high, it is mainly used in big cities. The second generation and the third generation of insulin will take the shape of stagger competition. According to the author's survey on some sample hospitals in China, the CAGR of insulin glargine in sample hospitals in China has exceeded 60% during the period of 2014- 2015. Currently, the Chinese market is dominated mainly by Aventis Behring Gmbh (the trade name of insulin glargine is Lantus and the sales in 2014 exceeded USD 7 billion) and the generic drugs (the trade name of insulin glargine is Basalin) made by Gan & Lee Pharmaceutical. As the patent of Lantus expired in February 2015, the global market structure is estimated to change in the next few years. On September 9th 2014, Eli Lilly and Company and Boehringer- ingelheim issued a joint statement that the insulin biosimilar - insulin glargine owned by them has been approved to come into market by the EU. On the other hand, in the Chinese market, some local enterprises are also hastening the development of Lantus's generic drug. Companies Mentioned: - Gan & Lee Pharmaceuticals - Aventis Behring GmbH - Tonghua Dongbao Pharmaceutical Co., Ltd For more information visit http://www.researchandmarkets.com/research/62...estigation About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
LLY: 86.14 (+2.37)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Avoid FOGs: Illinois Water's Holiday PSA

Updated Category News Views 86

Don't Ignore the Kitchen Sink This Holiday You ever poured something down the drain and just prayed it wouldn't come back to bite you later? Well, Illinois American Water is throwing up a big, red flag about doing exactly that during the holidays. When we're all busy passing the gravy boat and diving into festive feasts, it's easy to forget the after-party might just turn...

Continue Reading
Local Bounti Expands: Acquires CEA Facilities

Updated Category News Views 17

Local Bounti's Strategic Acquisition Move Local Bounti's at it again, shaking up the indoor agriculture scene by snapping up some real estate from Revol Greens. We're talking 30 acres of primo certified-organic greenhouse space across Texas and Minnesota. And they’re picking these babies up right as they’re ready to grow, not like some flashy land grab. Digging into...

Continue Reading
Copper Peptides Shine in New Renue Blue Cream

Updated Category News Views 0

Renue By Science's Ambitious Skincare Launch Alright, we've got a big player stepping up in the realm of skincare with a new face cream packed tightly with science-backed goodies. Renue By Science is revamping their game by anchoring their new Renue Blue Face Cream around the star of the moment: copper tripeptide-1, also known as GHK-Cu. This is more than a beauty gloss...

Continue Reading
Caregiving's Financial Impact on Women: Insights from Cinergy

Updated Category News Views 84

Women Caregivers Face Financial Crossroads When it comes down to it, caregiving is one heck of a responsibility, particularly for women. It's about the sacrifices they make, not just in time but in financial security, too. Step away from a job to care for someone, and it's a dicey game you're playing with future income. The Cost of Generosity: Financial Impacts Cindy...

Continue Reading
iHeartMedia Faces 65% Drop: Fraud Investigation Launched

Updated Category News Views 0

Trouble Tunes for iHeartMedia Investors Alright folks, here's the skinny on iHeartMedia, Inc. These days, it's like everyone's out for a piece of iHeart, and not in the way you'd wanna see—unless you're SBS Law, those shareholder rights hotshots diving into another pond of legal ripples. Seems a heap of head-scratching's going down on their version of transparency with...

Continue Reading
YYForce's Strategic Play: Robotics and AI Expansion

Updated Category News Views 28

Innovation Meets Pragmatism at YYForce There's a new bout of excitement brewing over at YYForce Inc. (NASDAQ: YFOR), if the latest announcements are anything to go by. The Singapore-based AI-enabled workforce dynamo is laying out priorities like a general plotting a campaign—pragmatic, strategic, and with a keen eye on the bottom line. Aiming for a Technological Edge In...

Continue Reading
DemandTec Leads the Pack in Retail Pricing Arena

Updated Category News Views 70

DemandTec's Climb to Retail Pricing Stardom The news hitting the streets is that DemandTec's carved out a top spot in QKS Group's SPARK Matrix™ for Intelligent Retail Pricing & Promotion Optimization for 2026. In an industry filled with slick operators and gimmicks, it takes some real chops to stand out. They've clinched this position by rolling out a platform that ties...

Continue Reading
Alliance for Women in Media Champions Change in 2026

Updated Category News Views 39

A Celebration of Trailblazing Women in Media If there's one thing I've learned about strong leadership, it's that you can't fake authenticity. Today, we're tipping our hats to some genuine trailblazers. The Alliance for Women in Media (AWM) held its annual Gracies Leadership Awards, celebrating the achievements and vision of seven remarkable women. Honoring the...

Continue Reading
OFRM Faces Legal Heat Over Toddler Snack Recall

Updated Category News Views 51

OFRM Under the Microscope: Who Saw This Coming? Smack dab in the middle of navigating everyday market volatility, here's Once Upon A Farm (NYSE: OFRM) taking the spotlight—but for all the wrong reasons. The company got slapped with a stark FDA warning. Their Tractor Wheels toddler snacks allegedly pose a choking risk— think 'dry, sticky mass' refusing to budge with...

Continue Reading
Tenax Therapeutics Facing Class Action: DEC 28 Deadline

Updated Category News Views 70

Legal Storm Over Tenax Therapeutics Just what the doctor didn't order—legal headaches for Tenax Therapeutics, Inc. (NASDAQ:TENX). Yup, folks, buckle up because we're diving into another class action mudslinging match that’s setting the markets wagging. Berger Montague's law trebuchet is aimed squarely at Tenax and every investor should know the target’s outline....

Continue Reading

Top 5 Most Recently Viewed Articles

GrandCare Health Services Enhances Revenue with Smart Solutions

Updated Category News Views 120

GrandCare Health Services Takes a New Approach to Revenue Management In a strategic move to enhance its financial efficiency, GrandCare Health Services has recently partnered with Homecare Homebase (HCHB), a leading provider of cloud-based technological solutions designed for home health agencies. This collaboration specifically focuses on optimizing revenue cycle...

Continue Reading
Westland Insurance Expands its Ontario Footprint with Acquisition

Updated Category News Views 216

Westland Insurance Expands its Ontario Presence Westland Insurance, a prominent name in Canada’s insurance market, has made strides in enhancing its reach with the acquisition of Paul Ayotte Insurance Brokers Ltd. This strategic move aims to solidify Westland’s footprint in Ontario, allowing for improved service delivery to local clients. This acquisition not only...

Continue Reading
First Industrial Realty Trust Set for Q3 Results Conference Call

Updated Category News Views 50

First Industrial Realty Trust, Inc. (NYSE: FR) faced a pivotal moment back in late 2024, gearing up to unveil its third-quarter numbers. The desks were buzzing as traders anticipated this call—a regular event but always loaded with potential surprises. Q3 Results Anticipation: Supply Chain Stakes or Investor Optimism? On that Thursday morning, scheduled for 10:00 a.m....

Continue Reading
Fannie Mae Panel Predicts Slowdown in Future Home Prices

Updated Category News Views 217

Fannie Mae's Expert Insights on Home Price Trends A recent survey conducted by Fannie Mae proves insightful for those watching the housing market, as it sheds light on anticipated changes in home prices in the coming years. The report indicates that after an increase of 5.3% in 2024, experts expect a more moderate growth of approximately 2.4% for 2025 and 2.1% for 2026....

Continue Reading
PenKid Biomarker Revolutionizes Kidney Therapy Decisions

Updated Category News Views 31

The Emergence of PenKid in Critical Care You ever get the feeling that the old ways just aren’t cutting it anymore? That’s where this penKid news rolls in like a breath of fresh air. In the world of ICU management, especially with kidney replacement therapy (KRT), this little biomarker is flipping the script on traditional biomarkers. Imagine 1,436 critically ill...

Continue Reading